Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07475026 Tislelizumab Hepatocellular Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07475026 clinical trial report covering Tislelizumab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07473427 Live attenuated varicella vaccine(Sinovac Biotech) Chickenpox Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07473427 clinical trial report covering Live attenuated varicella vaccine(Sinovac Biotech), Phase 3, endpoints, sponsor, geography, readout timing and d
Latest Hotspot
8 min read
NCT07473843 Zodasiran Homozygous familial hypercholesterolemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07473843 clinical trial report covering Zodasiran, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07473128 Trilaciclib Dihydrochloride Small cell lung cancer limited stage Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07473128 clinical trial report covering Trilaciclib Dihydrochloride, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07474649 Atorvastatin Calcium Coronary Artery Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07474649 clinical trial report covering Atorvastatin Calcium, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07472413 Cetirizine Hydrochloride Multiple Sclerosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07472413 clinical trial report covering Cetirizine Hydrochloride, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20250317 Tuberculin purified protein derivative(Coen biotech) Tuberculosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
CTR20250317 clinical trial report covering Tuberculin purified protein derivative(Coen biotech), Phase 3, endpoints, sponsor, geography, readout timing and
Latest Hotspot
8 min read
NCT07476898 Tenecteplase Ischemic stroke Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07476898 clinical trial report covering Tenecteplase, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20260953 Acoltremon Xerophthalmia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
CTR20260953 clinical trial report covering Acoltremon, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07477808 Megestrol Acetate Non-Small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07477808 clinical trial report covering Megestrol Acetate, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07475949 Tenecteplase Acute Ischemic Stroke Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07475949 clinical trial report covering Tenecteplase, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600120718 Tapinarof Psoriasis of scalp Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
ChiCTR2600120718 clinical trial report covering Tapinarof, Phase 3, endpoints, sponsor, geography, readout timing and development white space.